Skip to Main Content

++

INTRODUCTION

++

penciclovir (pen-sye-kloe-veer)

Denavir

Classification

Therapeutic: antivirals (topical)

Pharmacologic: nucleoside analogues

++
Indications
++

Recurrent herpes labialis (cold sores).

++
Action
++

Inhibits viral DNA synthesis and replication. Therapeutic Effects: Death of herpes virus. Decreases lesion duration and pain. Active against herpes viruses.

++
Adverse Reactions/Side Effects
++

CNS: headache. Local: application site reactions.

++

PHYSICAL THERAPY IMPLICATIONS

++
Examination and Evaluation
++

  • Assess skin and mucosal lesions to help document whether drug therapy is successful in controlling infection. Report any local irritation or inflammation at the application site.

++
Interventions
++

  • Avoid contact with cutaneous or mucosal lesions when treating patient.

  • Always wash hands thoroughly and disinfect equipment (whirlpools, electrotherapeutic devices, treatment tables, and so forth) to help prevent the spread of infection. Employ universal precautions as indicated for specific patients.

++
Patient/Client-Related Instruction
++

  • Advise patient to apply medication as directed. Penciclovir should not be used more frequently or longer than prescribed.

  • Remind patient that penciclovir does not cure herpes infections. The virus lies dormant in nerve cells, and this drug will not prevent the spread of infection to others.

  • Instruct patient and family/caregivers to report other troublesome side effects, including severe or prolonged headache.

++
Pharmacokinetics
++

Absorption: Not absorbed following topical use.

++

Distribution: Unknown.

++

Metabolism and Excretion: Converted intracellularly to active triphosphate form; excreted in urine.

++

Half-life: 2–2.5 hr.

++

Table Graphic Jump Location
Favorite Table | Download (.pdf) | Print

TIME/ACTION PROFILE

ROUTE ONSET PEAK DURATION
topical unknown unknown unknown

++
Contraindications/Precautions
++

Contraindicated in: Hypersensitivity to penciclovir or other components of the formulation.

++

Use Cautiously in: Pregnancy, lactation, or children (safety not established).

++
Interactions
++

Drug-Drug: None significant.

++
Route/Dosage
++

PO (Adults): Apply 1% cream q 2 hr for 4 days while awake.

++
Availability
++

Cream: 1% in 2-g tubes.

Pop-up div Successfully Displayed

This div only appears when the trigger link is hovered over. Otherwise it is hidden from view.